Search results (6)
« Back to NewsProfessor Eileen Parkes appointed to lead Oxford’s Experimental Cancer Medicine Centre
17 October 2023
Eileen Parkes, Associate Professor in Innate Tumour Immunology in the Department of Oncology, will lead the expansion of the centre’s programmes in early drug development and biomarker research.
Oxford to launch UK’s first trials unit dedicated to conducting precision prevention and early detection studies
27 July 2023
Oxford researchers have been given a £1 million boost to support their strategy of developing cancer prevention treatments and early diagnostic tools for people at high risk of cancer.
Multi-cancer blood test shows real promise in NHS trial
2 June 2023
An NHS trial of a new blood test for more than 50 types of cancer correctly revealed two out of every three cancers in more than 5,000 people who had visited their GP with suspected symptoms, in England or Wales. The test also correctly identified the original site of cancer in 85% of those cases.
Funding to research metformin’s ability to delay or prevent cancers driven by the mutated TP53 gene
29 September 2022
A research project embedded within the Metformin in Li Fraumeni (MILI) trial will investigate metformin’s mechanism of action when taken as a preventative for mTP53-driven cancers.
World’s first cancer prevention trial to test diabetes drug in patients with high-risk genetic condition
24 November 2021
Oxford researchers will lead a £2m national cancer prevention trial to assess the benefit a diabetes drug has in patients with Li Fraumeni Syndrome (LFS), a genetic condition that impacts 1 in 20,000 people worldwide and puts them at a 70-90% lifetime risk of cancer.